Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

Inclusion Criteria Subjects must meet all of the following criteria to be enrolled: 1. Aged 18 to 75 years, regardless of sex; 2. Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification; 3. ECOG performance status of 0-2; 4. Expected survival of at least 3 months; 5. CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry; 6. Patients who are resistant/refractory to CD19 CAR-T cell therapy or have low CD19 expression; 7. No severe cardiac, pulmonary, hepatic, or renal disease; 8. Able to understand and willing to sign the informed consent form for this study; 9. No contraindications to peripheral blood mononuclear cell collection/apheresis; 10. At least one measurable and evaluable lesion according to RECIST 1.1; 11. Must have previously received standard first-line and second-line therapy; 12. No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria Subjects meeting any of the following criteria will be excluded: 1. History of allergy to any component of the cell product; 2. Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L; 3. Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST \>2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL; 4. New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) \<50% on echocardiography; 5. Abnormal pulmonary function, with oxygen saturation \<92% on room air; 6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant severe cardiac disease within 12 months prior to enrollment; 7. Grade 3 hypertension with poor blood pressure control despite medication; 8. History of craniocerebral trauma, disturbance of consciousness, epilepsy, severe cerebral ischemia, or cerebral hemorrhagic disease; 9. Presence of autoimmune disease, immunodeficiency, or other conditions requiring immunosuppressive therapy; 10. Presence of uncontrolled active infection; 11. Prior treatment with any CAR-T cell product or other genetically modified T-cell therapy; 12. Receipt of a live vaccine within 4 weeks prior to enrollment; 13. Positive for HIV, HBV, HCV, or TPPA/RPR, or HBV carrier status; 14. History of alcohol abuse, drug abuse, or psychiatric illness; 15. Participation in any other clinical study within 3 months prior to enrollment in this study; 16. Female subjects meeting any of the following conditions: 1. currently pregnant or breastfeeding; 2. planning to become pregnant during the study period; or 3. of childbearing potential and unwilling or unable to use effective contraception; 17. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.